NCT03659149View on ClinicalTrials.gov

Pharmacokinetics and Safety Profile of CKD-333

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 8, 2018

Primary Completion Date

October 5, 2018

Study Completion Date

October 12, 2018

Conditions
HypertensionDyslipidemias
Interventions
DRUG

CKD-333 formulation I

1 tablet administered before the breakfast(single-dose)

DRUG

CKD-333 formulation II

1 tablet administered before the breakfast(single-dose)

DRUG

CKD-330+D086

2 tablet administered before the breakfast(single-dose)

Trial Locations (1)

Unknown

Seoul Saint Mary's Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT03659149 - Pharmacokinetics and Safety Profile of CKD-333 | Biotech Hunter | Biotech Hunter